2-溴-4-硝基苯甲酰氯 | 856794-72-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-溴-4-硝基苯甲酰氯
• 英文名称: 2-bromo-4-nitrobenzoyl chloride
• CAS: 856794-72-4
• 化学式: C₇H₃BrClNO₃
• 分子量: 264.463
• InChiKey: NBTMVUPANYTSDJ-UHFFFAOYSA-N

物化性质

• 熔点：
  132-133 °C
• 沸点：
  318.9±22.0 °C(Predicted)
• 密度：
  1.838±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-溴-4-硝基苯甲酰氯 在 N-甲基吗啉 、 盐酸 、 4-二甲氨基吡啶 、 四(三苯基膦)钯 、 tin(II) chloride dihdyrate 、 potassium carbonate 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.7h， 生成 methyl 2'-(benzylcarbamoyl)-5'-((S)-2-((S)-3-(4-((bis-(dimethylamino)phosphoryl)oxy)phenyl)-2-(4-cyanobenzamido)propanamido)-4-methylpentanamido)-[1,1'-biphenyl]-4-carboxylate
  参考文献：
  名称：

  Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein

  摘要：

  Aberrant activation of oncogenic signal transducer and activator of transcription 3 (STAT3) protein signaling pathways has been extensively implicated in human cancers. Given STAT3's prominent dysregulatory role in malignant transformation and tumorigenesis, there has been a significant effort to discover STAT3-specific inhibitors as chemical probes for defining the aberrant STAT3-mediated molecular events that support the malignant phenotype. To identify novel, STAT3-selective inhibitors suitable for interrogating STAT3 signaling in tumor cells, we explored the design of hybrid molecules by conjugating a known STAT3 inhibitory peptidomimetic, ISS610 to the high-affinity STAT3-binding peptide motif derived from the ILR/gp-130. Several hybrid molecules were examined in in vitro biophysical and biochemical studies for inhibitory potency against STAT3. Lead inhibitor 14aa was shown to strongly bind to STAT3 (K-D = 900 nM), disrupt STAT3: phosphopeptide complexes (K-i = 5 mu M) and suppress STAT3 activity in in vitro DNA binding activity/electrophoretic mobility shift assay (EMSA). Moreover, lead STAT3 inhibitor 14aa induced a time-dependent inhibition of constitutive STAT3 activation in v-Src transformed mouse fibroblasts (NIH3T3/v-Src), with 80% suppression of constitutively-active STAT3 at 6 h following treatment of NIH3T3/v-Src. However, STAT3 activity recovered at 24 h after treatment of cells, suggesting potential degradation of the compound. Results further showed a suppression of aberrant STAT3 activity in NIH3T3/v-Src by the treatment with compound 14aa-OH, which is the non-pTyr version of compound 14aa. The effect of compounds 14aa and 14aa-OH are accompanied by a moderate loss of cell viability. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.12.010
• 作为产物：
  描述：

  2-溴-4-硝基甲苯 在 吡啶 、 potassium permanganate 、 氯化亚砜 作用下， 以 水 为溶剂， 反应 18.0h， 生成 2-溴-4-硝基苯甲酰氯
  参考文献：
  名称：

  无水氯化锡催化新型吡咯并苯并氧杂硼骨架骨架的合成及其通过Friedel-Crafts反应的衍生化

  摘要：

  摘要从2-溴-1-经六步合成了一种新型的吡咯并苯并恶唑硼酸酯6-（吡咯-1-基）-1,3-二氢-1-羟基-2,1-苯并恶硼酸酯，其总收率为27％。以甲基-4-硝基苯为原料。它的衍生化是通过无水锡氯化物与各种酰基氯催化的Friedel-Crafts反应实现的，从而以3-酰基-1-苯基吡咯为主要产物。

  DOI：

  10.1016/j.cclet.2011.06.005

文献信息

• Nonsteroidal gestagens
  申请人：Schering Aktiengesellschaft

  公开号：US06344454B1

  公开（公告）日：2002-02-05

  This invention describes the new, nonsteroidal gestagens of general formula I in which A, B, Ar, R1, R2 and R3 have the meanings that are indicated in more detail in the description. The new compounds show a very great affinity to the gestagen receptor. They can be used alone or in combination with estrogens in contraceptive preparations. In addition, they can be used for treating endometriosis. Together with estrogens, they can also be used in preparations for treating gynecological disorders, for treating premenstrual symptoms and for substitution therapy. Based on the androgenic action, they can also be used for male birth control, male HRT and hormone therapy and for treating andrological disease agents.

  本发明描述了具有一般公式 I 的新非甾体孕激素：其中 A、B、Ar、R1、R2 和 R3 的含义在描述中更详细地指出。这些新化合物对孕激素受体的亲和力非常强。它们可以单独使用，也可以与雌激素结合用于避孕制剂中。此外，它们还可以用于治疗子宫内膜异位症。与雌激素结合时，它们还可用于治疗妇科疾病、治疗经前症状和替代疗法。基于其雄激素作用，它们还可用于男性避孕、男性激素替代疗法和激素治疗，以及治疗男科疾病。
• Scope and Mechanism of a True Organocatalytic Beckmann Rearrangement with a Boronic Acid/Perfluoropinacol System under Ambient Conditions
  作者：Xiaobin Mo、Timothy D. R. Morgan、Hwee Ting Ang、Dennis G. Hall

  DOI：10.1021/jacs.8b01618

  日期：2018.4.18

  enylboronic acid were identified as efficient catalysts for the direct and chemoselective activation of oxime N-OH bonds in the Beckmann rearrangement. This classical organic reaction provides a unique approach to prepare functionalized amide products that may be difficult to access using traditional amide coupling between carboxylic acids and amines. Using only 5 mol % of boronic acid catalyst and

  羟基官能团的催化活化对于药物和商品化学品的生产具有重要意义。在这里，2-烷氧基羰基-和 2-苯氧基羰基-苯基硼酸被确定为在贝克曼重排中直接和化学选择性活化肟 N-OH 键的有效催化剂。这种经典的有机反应提供了一种独特的方法来制备官能化的酰胺产物，使用传统的羧酸和胺之间的酰胺偶联可能难以获得这些产物。在极性溶剂混合物中仅使用 5 mol% 的硼酸催化剂和全氟频哪醇作为添加剂，操作简单的方案具有条件温和、底物范围广和官能团耐受性高的特点。种类繁多的二芳基、芳基-烷基、杂芳基-烷基、和二烷基肟在环境条件下反应以提供高产率的酰胺产物。游离醇、酰胺、羧酸酯和许多其他官能团与反应条件相容。对催化循环的研究揭示了一种新型的硼诱导的肟酯交换，它提供了一种酰基肟中间体，参与了完全催化的非自蔓延贝克曼重排机制。酰基肟中间体独立制备并经受反应条件。它被发现是自给自足的；它反应迅速，单分子，不需要游离肟。一系列对照实验和
• [EN] PYRAZINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRAZINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014072257A1

  公开（公告）日：2014-05-15

  The present invention relates to compounds of formula (I), wherein R1R2 are hydrogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cycloalkyl, OCH2-cycloalkyl or heterocycloalkyl which is optionally substituted by halogen, with the proviso that one of R1 and R2 is hydrogen, or R1 and R2 form together with the carbon atom to which they are attach a phenyl ring, which may be optionally substituted by lower alkyl; R3/R4 are hydrogen, halogen or cyano; with the proviso that one of R3 and R4 is hydrogen; or to a pharmaceutically suitable acid addition salt thereof, to all racemic mixtures, all their corresponding enantiomers and/or optical isomers, which may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式(I)的化合物，其中R1R2为氢、较低的烷基、较低的烷氧基、受卤素取代的较低烷基、受卤素取代的较低烷氧基、环烷基、OCH2-环烷基或杂环烷基，该杂环烷基可以选择性地受卤素取代，但R1和R2中的一个为氢，或者R1和R2与它们连接的碳原子一起形成苯环，该苯环可以选择性地受较低烷基取代；R3/R4为氢、卤素或氰基；但R3和R4中的一个为氢；或其药学上适宜的酸盐，所有的外消旋混合物，它们对应的对映体和/或光学异构体，可用于治疗抑郁症、焦虑症、躁郁症、注意缺陷多动障碍（ADHD）、与压力有关的疾病、精神疾病、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用、代谢紊乱、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍，以及心血管疾病。
• Enantioselective Synthesis of Axially Chiral Biaryls by the Pd-Catalyzed Suzuki−Miyaura Reaction: Substrate Scope and Quantum Mechanical Investigations
  作者：Xiaoqiang Shen、Gavin O. Jones、Donald A. Watson、Brijesh Bhayana、Stephen L. Buchwald

  DOI：10.1021/ja104297g

  日期：2010.8.18

  computational studies used to determine the origin of stereoselectivity during the selectivity-determining reductive elimination step of the related coupling of tolyl boronic acid with naphthylphosphonate bromide that was reported in a previous publication (J. Am. Chem. Soc. 2000, 122, 12051-12052). These studies indicate that the stereoselectivity arises from a combination of weak -(C)H..O interactions

  我们报告了轴向手性联芳酰胺的有效合成，产率范围为 80-92%，对映选择性范围为 88-94% ee，采用不对称 Suzuki-Miyaura 工艺，Pd(OAc)(2) 和 KenPhos 作为配体。这些研究表明，富电子和缺电子的邻卤苯甲酰胺可以与 2-甲基-1-萘基硼酸和 2-乙氧基-1-萘基硼酸有效偶联。反应的产率和选择性与苯甲酰胺偶联伙伴上卤素取代基的性质无关。我们的研究表明，轴向手性杂环和联苯化合物也可以用这种方法合成。我们还报告了用于确定在甲苯基硼酸与萘基膦酸酯溴化物相关偶联的选择性决定还原消除步骤期间立体选择性起源的计算研究，该步骤在之前的出版物中报道过 (J. Am. Chem. Soc. 2000, 122 , 12051-12052)。这些研究表明，立体选择性源于弱 -(C)H..O 相互作用以及 CC 偶联过渡态中甲苯基和萘基膦酸酯加合物之间的空间相互作用。
• [EN] NITRO AND AMINO SUBSTITUTED TOPOISOMERASE AGENTS<br/>[FR] AGENTS DE LA TOPOISOMERASE SUBSTITUES PAR NITRO ET AMINO
  申请人：UNIV RUTGERS

  公开号：WO2004014918A1

  公开（公告）日：2004-02-19

  The invention provides compounds of formula (I): wherein R1-R9, W, and X have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula (I), and therapeutic methods for treating cancer using compounds of formula (I).

  该发明提供了公式（I）的化合物：其中R1-R9、W和X具有规范中定义的任何含义，以及它们的药用盐。该发明还提供了包含公式（I）化合物的药物组合物，制备公式（I）化合物的方法，用于制备公式（I）化合物的有用中间体，以及使用公式（I）化合物治疗癌症的治疗方法。